Allogene Therapeutics (NASDAQ:ALLO) Raised to Outperform at Citizens Jmp

Citizens Jmp upgraded shares of Allogene Therapeutics (NASDAQ:ALLO) from a market perform rating to an outperform rating in a research report report published on Friday morning, Marketbeat.com reports. Citizens Jmp currently has $5.00 target price on the stock.

A number of other brokerages also recently issued reports on ALLO. William Blair reissued an “outperform” rating on shares of Allogene Therapeutics in a report on Thursday, November 14th. Piper Sandler lowered their price target on shares of Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating on the stock in a report on Thursday, November 14th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $9.40.

Allogene Therapeutics Stock Up 2.6 %

Shares of NASDAQ:ALLO opened at $1.94 on Friday. The firm has a market capitalization of $406.76 million, a PE ratio of -1.24 and a beta of 1.02. Allogene Therapeutics has a twelve month low of $1.32 and a twelve month high of $4.89. The company has a 50-day moving average price of $1.94 and a two-hundred day moving average price of $2.32.

Allogene Therapeutics (NASDAQ:ALLO) last announced its quarterly earnings results on Thursday, March 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.06. Analysts anticipate that Allogene Therapeutics will post -1.28 earnings per share for the current fiscal year.

Insider Activity at Allogene Therapeutics

In related news, insider Timothy L. Moore sold 14,746 shares of the firm’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $1.71, for a total value of $25,215.66. Following the sale, the insider now directly owns 250,713 shares of the company’s stock, valued at $428,719.23. This trade represents a 5.55 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Zachary Roberts sold 27,199 shares of Allogene Therapeutics stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $1.78, for a total transaction of $48,414.22. Following the transaction, the executive vice president now directly owns 488,054 shares in the company, valued at $868,736.12. This trade represents a 5.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 52,710 shares of company stock valued at $92,125 over the last three months. 24.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in ALLO. Cibc World Markets Corp purchased a new position in shares of Allogene Therapeutics during the fourth quarter worth approximately $26,000. PAX Financial Group LLC purchased a new position in shares of Allogene Therapeutics during the fourth quarter worth approximately $27,000. RPO LLC purchased a new position in shares of Allogene Therapeutics during the fourth quarter worth approximately $31,000. Caption Management LLC purchased a new position in shares of Allogene Therapeutics during the fourth quarter worth approximately $32,000. Finally, Syon Capital LLC purchased a new position in shares of Allogene Therapeutics during the fourth quarter worth approximately $39,000. 83.63% of the stock is owned by hedge funds and other institutional investors.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).